Information Provided By:
Fly News Breaks for January 19, 2016
ANY, PSTG, NVCR, CSRA, ADMS, ARIA
Jan 19, 2016 | 10:03 EDT
Today's noteworthy initiations include: ARIAD (ARIA) initiated with an Underweight at Barclays... Adamas Pharmaceuticals (ADMS) initiated with a Neutral at Mizuho... CSRA (CSRA) initiated with an Outperform at RBC Capital... Novocure (NVCR) initiated with an Underweight at Barclays... Pure Storage (PSTG) initiated with a Buy at Lake Street... Sphere 3D (ANY) initiated with a Buy at Ladenburg.
News For ARIA;ADMS;CSRA;NVCR;PSTG;ANY From the Last 2 Days
NVCR
Mar 27, 2024 | 16:24 EDT
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1... To see the rest of the story go to thefly.com. See Story Here
NVCR
Mar 27, 2024 | 12:00 EDT
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.  1... To see the rest of the story go to thefly.com. See Story Here
NVCR
Mar 27, 2024 | 09:36 EDT
Zai Lab (ZLAB) said its partner Novocure (NVCR) announced the Phase 3 METIS clinical trial met its primary endpoint, demonstrating a statistically significant improvement in time to intracranial progression for adult patients treated with Tumor Treating Fields therapy and supportive care compared to supportive care alone in the treatment of patients with 1-10 brain metastases from non-small cell lung cancer following stereotactic radiosurgery. Patients treated with TTFields therapy and supportive care exhibited a median time to intracranial progression of 21.9 months compared to 11.3 months in patients treated with supportive care alone for brain metastasis . Preliminary analyses of key secondary endpoints did not demonstrate statistical significance. Novocure intends to submit these data to regulatory authorities. Zai Lab said it contributed to the METIS trial and achieved treatment of the first patient in Greater China in May 2021.